Pandox AB (FRA:POX) Research & Development: €0.0 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:POX Pandox AB FRA:POX
73 GF Score
Price €15.72
GF Value €17.30
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Pandox AB Research & Development?

Pandox AB FRA:POX -0.38% 73 Research & Development is €0.0 Mil as of Jun. 2026. GuruFocus rates FRA:POX with a GF Score™ of 73/100 and a GF Value™ of €17.30 (Fairly Valued). The stock has 7 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Pandox AB's Research & Development for the three months ended in Jun. 2026 was €0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 was €0.0 Mil.

Pandox AB  (FRA:POX) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Pandox AB Research & Development Related Terms

Pandox AB Research & Development Historical Data

* Premium members only.

The historical data trend for Pandox AB's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pandox AB Research & Development Chart

Pandox AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Pandox AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:POX
73GF Score
Pandox AB FRA:POX
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pandox AB Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0.0 Mil mean?
Pandox AB (FRA:POX) has a Research & Development of €0.0 Mil as of Jun. 2026. Research and development expense is the total cost for research and development activities. View historical data on Pandox AB and its competitors.
Is Pandox AB's Research & Development too high?
Pandox AB's current Research & Development is €0.0 Mil. Overall, Pandox AB has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pandox AB's Research & Development compare to CBRE and BEKE?
Pandox AB's Research & Development of €0.0 Mil can be compared against companies in the Real Estate industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Real Estate company?
A good Research & Development depends on the Real Estate industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Pandox AB and its competitors. Pandox AB's current Research & Development is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pandox AB stock overvalued right now?
Based on GuruFocus' analysis, Pandox AB (FRA:POX) is currently considered Fairly Valued. The stock's GF Value™ is €17.30, compared to a current price of €15.72 — trading 9.1% below its estimated fair value. The current Research & Development is €0.0 Mil. Pandox AB's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Pandox AB (FRA:POX), the current Research & Development is €0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pandox AB (FRA:POX) Overvalued in 2026?

Based on GuruFocus' analysis, Pandox AB stock appears to be undervalued. The current stock price of €15.72 is trading 9.1% below its estimated GF Value™ of €17.30. GuruFocus considers Pandox AB to be Fairly Valued.

Key valuation signals for FRA:POX:

  • Research & Development: €0.0 Mil
  • GF Value™: €17.30 vs. price of €15.72 (9.1% below fair value)
  • GF Score™: 73/100 with 7 warning signs

No single metric tells the full story. See the FRA:POX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pandox AB Business Description

Other Exchanges PNDX B:Sweden0R8U:UK
Address Vasagatan 11, 9th floor, Box 15, Stockholm, SWE, SE-101 20
Pandox AB is a hotel property company focused on owning, developing, and leasing hotel properties to hotel operators, with its business concept based on long-term, revenue-based leases with guaranteed minimum levels. It also operates certain hotels itself as part of its ownership. Its activities include property management, property development, and portfolio optimisation, along with leasing hotel properties and operating hotels under its Own Operations segment. The Company operates through two main segments, namely Leases, which contributes the maximum revenue and is the core business with long-term revenue-based lease agreements, and Own Operations, where the Company operates hotels in its own properties. Geographically, Pandox has a presence across Europe.
73GF Score

Get the complete analysis for FRA:POX

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€15.72
Price
€17.30
GF Value